PFA Pension Forsikringsaktieselskab Takes $57.58 Million Position in CVS Health Corporation $CVS

Key Points

• PFA Pension bought a new position of 721,071 CVS shares valued at about $57.58 million, leaving the fund with roughly 0.06% of the company while institutional investors collectively own about 80.66% of CVS.
• CVS beat Q1 expectations with $1.09 EPS and revenue of $105.69 billion (up 8.2% year‑over‑year), set FY2026 guidance of 5.940–6.140 EPS, and has an average analyst target of about $95.05 with the majority of analysts rating the stock a Buy.
• The company announced a quarterly dividend of $0.665 (3.2% yield) despite a high payout ratio (192.75%), and faces mixed catalysts—regulatory tailwinds, automation and health‑services expansion versus near‑term margin pressures and rich valuation that have contributed to recent stock weakness.

PFA Pension Forsikringsaktieselskab bought a new stake in CVS Health Corporation (NYSE:CVS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 721,071 shares of the pharmacy operator's stock, valued at approximately $57,578,000. PFA Pension Forsikringsaktieselskab owned about 0.06% of CVS Health at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd lifted its holdings in CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock worth $26,000 after buying an additional 281 shares during the period. Ares Financial Consulting LLC bought a new stake in shares of CVS Health in the 4th quarter worth approximately $29,000. Corundum Trust Company INC bought a new stake in shares of CVS Health in the 3rd quarter worth approximately $29,000. GoalVest Advisory LLC bought a new stake in shares of CVS Health in the 4th quarter worth approximately $32,000. Finally, SOA Wealth Advisors LLC. grew its position in shares of CVS Health by 36.9% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator's stock worth $37,000 after buying an additional 131 shares during the last quarter. Institutional investors own 80.66% of the company's stock.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Regulatory tailwinds for Aetna and clearer PBM policy raised upside visibility for CVS’s Health Services and PBM businesses, boosting investor optimism about Medicare Advantage payments and reduced insulin‑pricing uncertainty. Regulatory Tailwinds Article
• Positive Sentiment: Operational efficiency gains from automation: WSJ reports on CVS’s new highly automated distribution center using robots to move millions of items with far fewer staff — a potential long‑term margin lever. Robotics/Operations Article
• Positive Sentiment: Competitive positioning: coverage notes CVS is pushing health‑services expansion while Walgreens pulls back, which could support share gains in higher‑margin care services. Competitive Positioning Article
• Neutral Sentiment: Earnings preview / analyst focus: Wall Street is parsing Q1 metrics (revenue, pharmacy trends and Health Services growth). Investors are waiting for the company’s March‑quarter results and management color before re‑rating shares. Earnings Countdown Article
• Negative Sentiment: Near‑term margin risk: earnings previews caution that benefits segment pressures and elevated costs could weigh on Q1 results, a key reason investors are cautious ahead of the print. Earnings Preview Article
• Negative Sentiment: Market dynamics and valuation: after a strong run-up, the stock’s rich near‑term multiples and lighter intraday volume can amplify down‑moves as investors lock in gains while awaiting Q1 clarity (contributing to today’s pullback).

CVS Health Stock Down 1.4%

Shares of NYSE:CVS opened at $82.12 on Friday. CVS Health Corporation has a 52-week low of $58.35 and a 52-week high of $85.15. The firm has a market capitalization of $105.24 billion, a P/E ratio of 59.51, a P/E/G ratio of 0.86 and a beta of 0.60. The stock has a 50 day moving average price of $76.32 and a 200-day moving average price of $77.97. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84.

CVS Health (NYSE:CVS - Get Free Report) last announced its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The firm had revenue of $105.69 billion during the quarter, compared to analyst estimates of $103.67 billion. During the same quarter in the prior year, the company earned $1.19 EPS. The business's revenue was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, equities research analysts anticipate that CVS Health Corporation will post 7.14 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd will be issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Thursday, April 23rd. CVS Health's payout ratio is 192.75%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CVS. Robert W. Baird lifted their price objective on CVS Health from $92.00 to $94.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 15th. Argus cut their price objective on CVS Health from $91.00 to $90.00 and set a "buy" rating on the stock in a research report on Wednesday, January 28th. TD Cowen reiterated a "buy" rating on shares of CVS Health in a research report on Friday, March 13th. Sanford C. Bernstein raised CVS Health from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $91.00 to $94.00 in a research report on Thursday, March 12th. Finally, Bank of America decreased their target price on CVS Health from $100.00 to $95.00 and set a "buy" rating for the company in a research report on Tuesday, January 27th. Twenty research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, CVS Health currently has an average rating of "Moderate Buy" and an average target price of $95.05.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.